Get started
Author

Karam Aboud

ORCID: 0009-0000-8491-2178
Observed ORCID: 0009-0000-8491-2178
OpenAlex ID: A5030101775
Cytotoxic chemotherapy: clinical aspects
2022 · Karam Aboud, Magdalena Meissner, et al. · Medicine · 12
Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer
2025 · Karam Aboud, Magda Meissner, et al. · Therapeutic Advances in Medical Oncology · 7
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).
2024 · James F. Spicer, David James Pinato, et al. · Journal of Clinical Oncology · 5
Quality control of Warfarin Sodium tablets marketed in Syria
2017 · Mostafa Isbera, Karam Aboud, et al. · Research Journal of Pharmacy and Technology · 2
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours
2026 · Robert H. Jones, David J. Pinato, et al. · European Journal of Cancer · 1
Physical activity heterogeneity in COPD; meaningful analysis of data
2016 · Chris Newby, Karam Aboud, et al. · European Respiratory Journal · 1
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.
2024 · David James Pinato, Robert Hugh Jones, et al. · Journal of Clinical Oncology
Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma
2023 · Charlotte Bennett, Sian Morgan, et al. · BMJ Case Reports
PDF
Closing the Feedback Loop: Collaborative Design of a Musculoskeletal Revision Course
2018 · Charlotte Leahy, Hannah Hawrot, et al. · Journal of Learning and Teaching in Higher Education
PDF
Works count: 9
Citation count: 28
H-index: 3
I10-index: 1
Year
Topic
Type